
Verrica completes dosing in basal cell carcinoma immunotherapy trial
The phase 2 clinical trial of Verrica’s peptide-based immunotherapy for basal cell carcinoma has enrolled and dosed its final patient. VP-315, an oncolytic peptide, is injected directly into tumors to induce immunogenic cell death. The trial includes 80 patients with biopsy-proven BCC. Verrica’s VP-315 program aims to provide an alternative to surgery for BCC treatment,…